Gilead Sciences Inc (GILD)

[LongRun8]

GILD -- Priority review voucher

I wouldn't read too much into the "pediatric" nature of the voucher. The voucher was given to Sarepta due to their conditional approval of eteplirsen, for a rare pediatric disease. The actual priority review voucher can be used for any NDA or BLA, without regard to the indication or age group that the medication/biologic would be used for. So I wouldn't anticipate Gilead making any imminent purchase of a pharmaceutical company or a drug program targeting rare pediatric diseases.